The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

BACKGROUND: Sepsis and complications to sepsis are major causes of mortality in critically ill patients. Rapid treatment of sepsis is of crucial importance for survival of patients. The infectious status of the critically ill patient is often difficult to assess because symptoms cannot be expressed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Jensen, Jens-Ulrik, Lundgren, Bettina, Hein, Lars, Mohr, Thomas, Petersen, Pernille L, Andersen, Lasse H, Lauritsen, Anne Ø, Hougaard, Sine, Mantoni, Teit, Bømler, Bonnie, Thornberg, Klaus J, Thormar, Katrin, Løken, Jesper, Steensen, Morten, Carl, Peder, Petersen, J Asger, Tousi, Hamid, Søe-Jensen, Peter, Bestle, Morten, Hestad, Søren, Andersen, Mads H, Fjeldborg, Paul, Larsen, Kim M, Rossau, Charlotte, Thomsen, Carsten B, Østergaard, Christian, Kjær, Jesper, Grarup, Jesper, Lundgren, Jens D
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2008
Soggetti:
Study Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2491622/
https://ncbi.nlm.nih.gov/pubmed/18620598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-8-91
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi